What You Should Know:
– SubjectWell, a patient access marketplace connecting individuals with chronic health conditions to healthcare options, has acquired PatientCentra, a company specializing in global patient recruitment and personalized recruitment journeys. Financial details…
Continue Reading
INVEST 2024 will be back at the Ritz Hotel in Chicago, May 21-22, and we are once again on the hunt for novel startups who will pitch LIVE in front of venture capitalist judges….
Continue Reading
Researchers at the Wyss Institute at Harvard University have developed a microfluidic chip that can recreate some of the features of radiation-induced lung injury. The lungs are very sensitive to radiation, and this can…
Continue Reading
Healthcare data and analytics and tech-enabled services will be the sectors most impacted by generative AI, according to a survey by investment firm GSR Ventures.The survey, which included responses from more than 40 healthcare…
Continue Reading
What You Should Know:
– Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company forms a strategic partnership to advance novel therapeutics for patients with cancer.
– Through this…
Continue Reading
Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal…
Continue Reading
Personalized companion care protocols for novel oncology therapeutics, like those for multiple myeloma, are essential for patient success. These care models should be adaptable according to patient variations, resource levels and care site capabilities….
Continue Reading
What You Should Know:
Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).The collaboration between Flatiron Health and Penn Medicine will…
Continue Reading
Scientists at Purdue University have developed a microRNA therapy designed to slow tumor growth. The technology takes advantage of the tendency of several cancer types to express an excess of surface receptors that bind…
Continue Reading
Radionetics Oncology has initiated a Phase 1 clinical trial for 68Ga-R8760, a pioneering radioligand imaging agent designed to detect adrenocortical carcinoma. The study, R8760-101 (NCT05999292), focuses on assessing the agent’s safety and dosimetry. Dr….
Continue Reading
